secwatch.observer — SEC 8-K summary
======================================

Issuer:     VivoSim Labs, INC. (VIVS)
CIK:        0001497253
Form:       8-K
Filed at:   2026-08-06T12:05:23+00:00
Accession:  0001193125-26-336844
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VivoSim regains Nasdaq equity compliance; cash $10.1M; guides 500%+ revenue growth in FY2027
--------------------------------------------------------------------------------

- Regained Nasdaq compliance (Rule 5550(b)(1)) after $5M Eli Lilly milestone and $4M financing.
- Cash on hand as of Aug 3, 2026: ~$10.1M, reflecting recent inflows.
- Reiterates FY2027 guidance of 500%+ revenue growth from NAMs contract research services.
- Share count rose from 3.2M (June 30) to 13.4M (Aug 3) on warrant exercises.
- Received $5M milestone from Eli Lilly, $1M escrow release, and $4M gross proceeds financing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1497253/000119312526336844/0001193125-26-336844-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1497253/000119312526336844/vivs-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-336844

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer